

Elizabeth W Loder

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7899628/elizabeth-w-loder-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

105
papers

10,219
citations

28
h-index

101
g-index

111
ext. papers

24,457
ext. citations

6.1
avg, IF

6.72
L-index

#	Paper	IF	Citations
105	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Public Health</i> , 2022 , 22, 179	4.1	2
104	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 1-10	1.9	
103	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Health Services Research</i> , 2022 , 22, 114	2.9	2
102	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>International Journal of Technology Assessment in Health Care</i> , 2022 , 38, e13	1.8	5
101	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Value in Health</i> , 2022 , 25, 3-9	3.3	14
100	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Medicine</i> , 2022 , 20, 23	11.4	6
99	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Applied Health Economics and Health Policy</i> , 2022 , 20, 213	3.4	1
98	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>European Journal of Health Economics</i> , 2022 , 1	3.6	1
97	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 28, 146-155	1.9	0
96	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Journal of Medical Economics</i> , 2022 , 25, 1-7	2.4	1
95	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMJ, The</i> , 2022 , 376, e067975	5.9	8
94	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Pharmacoeconomics</i> , 2022 , 1	4.4	1
93	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. <i>Value in Health</i> , 2022 , 25, 10-31	3.3	35
92	Guidance relevant to the reporting of health equity in observational research: a scoping review protocol.. <i>BMJ Open</i> , 2022 , 12, e056875	3	0
91	Pravila PRISMA 2020.. <i>Medicina Fluminensis</i> , 2021 , 57, 444-465	0	7
90	Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. <i>BMJ, The</i> , 2021 , 375, n2233	5.9	24
89	Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1614-1621	27.4	32

88	PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. <i>BMJ, The</i> , 2021 , 372, n160	5.9	666
87	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>BMJ, The</i> , 2021 , 372, n71	5.9	4545
86	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>PLoS Medicine</i> , 2021 , 18, e1003583	11.6	286
85	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>Systematic Reviews</i> , 2021 , 10, 89	3	513
84	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>International Journal of Surgery</i> , 2021 , 88, 105906	7.5	461
83	Development of a checklist to detect errors in meta-analyses in systematic reviews of interventions: study protocol. <i>F1000Research</i> , 2021 , 10, 455	3.6	
82	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2021 , 134, 178-189	5.7	201
81	Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review. <i>Cephalalgia</i> , 2021 , 41, 760-773	6.1	8
80	Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2021 , 181, 317-328	11.5	23
79	The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. <i>Headache</i> , 2021 , 61, 60-68	4.2	21
78	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 , 74, 790-799	0.7	23
77	Ten (No, Make that 11) Ways the Migraine Mavens Have Changed the Conversation About Sexism in Medicine. <i>Headache</i> , 2020 , 60, 1042-1046	4.2	
76	Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board. <i>Headache</i> , 2020 , 60, 1000-1004	4.2	3
75	Workforce Gap Analysis in the Field of Headache Medicine in the United States. <i>Headache</i> , 2020 , 60, 478-481	4.1	10
74	Characteristics of Neuropsychiatric Mobile Health Trials: Cross-Sectional Analysis of Studies Registered on ClinicalTrials.gov. <i>JMIR MHealth and UHealth</i> , 2020 , 8, e16180	5.5	
73	Ten Eleven Things Not to Say to Healthcare Professionals During the Coronavirus Disease 2019 Pandemic. <i>Headache</i> , 2020 , 60, 1837-1845	4.2	2
72	Real-world effectiveness and tolerability of erenumab: A retrospective cohort study. <i>Cephalalgia</i> , 2020 , 40, 1511-1522	6.1	32
71	Awareness, usage and perceptions of authorship guidelines: an international survey of biomedical authors. <i>BMJ Open</i> , 2020 , 10, e036899	3	8

70	Disentangling placebo effects in the treatment of migraine. <i>Nature Reviews Neurology</i> , 2020 , 16, 657-658	5	1
69	Eleven Things Not to Say to Your Female Colleagues. <i>Headache</i> , 2019 , 59, 1846-1854	4.2	6
68	Underrepresentation of Women Among Authors of Invited Commentaries in Medical Journals-Where Are the Female Editorialists?. <i>JAMA Network Open</i> , 2019 , 2, e1913665	10.4	11
67	Further Questioning of the Significance of the Gepants: A Response. <i>Headache</i> , 2019 , 59, 1831	4.2	
66	Time's up for and as the default pronouns for doctors. <i>BMJ, The</i> , 2019 , 367, l6565	5.9	
65	Potential Benefits of Migraine-What Is It Good For?. <i>JAMA Neurology</i> , 2019 , 76, 250-251	17.2	1
64	The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?. <i>Headache</i> , 2019 , 59, 113-117	4.2	31
63	Calcitonin Gene-Related Peptide Monoclonal Antibody Treatments for Migraine. <i>JAMA Internal Medicine</i> , 2019 , 179, 421-422	11.5	4
62	Consideration of Costs and Open-Label Studies of Erenumab-Reply. <i>JAMA Neurology</i> , 2019 , 76, 236-237	17.2	2
61	Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. <i>JAMA Neurology</i> , 2018 , 75, 566-572	17.2	40
60	The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. <i>Headache</i> , 2018 , 58, 496-505	4.2	201
59	Migraine Pain Location and Measures of Healthcare Use and Distress: An Observational Study. <i>Pain Research and Management</i> , 2018 , 2018, 6157982	2.6	5
58	Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018. <i>Headache</i> , 2018 , 58 Suppl 3, 218-229	4.2	28
57	Risk of Stroke Associated With Use of Estrogen Containing Contraceptives in Women With Migraine: A Systematic Review. <i>Headache</i> , 2018 , 58, 5-21	4.2	41
56	Biomedical authors' awareness of publication ethics: an international survey. <i>BMJ Open</i> , 2018 , 8, e021283		6
55	Safety Problems With a Transdermal Patch for Migraine: Lessons From the Development, Approval, and Marketing Process. <i>Headache</i> , 2018 , 58, 1639-1657	4.2	6
54	Who Should Try New Antibody Treatments for Migraine?. <i>JAMA Neurology</i> , 2018 , 75, 1039-1040	17.2	19
53	Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies. <i>Headache</i> , 2017 , 57, 1243-1251	4.2	3

52	The comorbidity burden of patients with cluster headache: a population-based study. <i>Journal of Headache and Pain</i> , 2017 , 18, 76	8.8	18
51	Medication overuse headache: An entrenched idea in need of scrutiny. <i>Neurology</i> , 2017 , 89, 1296-1304	6.5	46
50	Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. <i>Cephalalgia</i> , 2016 , 36, 358-70	6.1	28
49	Amitriptyline Dose and Treatment Outcomes in Specialty Headache Practice: A Retrospective Cohort Study. <i>Headache</i> , 2016 , 56, 1626-1634	4.2	16
48	Validity of cluster headache diagnoses in an electronic health record data repository. <i>Headache</i> , 2016 , 56, 1132-6	4.2	7
47	A migraine management training program for primary care providers: An overview of a survey and pilot study findings, lessons learned, and considerations for further research. <i>Headache</i> , 2016 , 56, 725-40	4.2	22
46	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2016 , 56, 821-834	4.2	111
45	The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. <i>Headache</i> , 2015 , 55, 21-34	4.2	309
44	The prevalence, burden, and treatment of severe, frequent, and migraine headaches in US minority populations: statistics from National Survey studies. <i>Headache</i> , 2015 , 55, 214-28	4.2	55
43	Registration status and outcome reporting of trials published in core headache medicine journals. <i>Neurology</i> , 2015 , 85, 1789-94	6.5	16
42	Headache Rounds: Sudden, Transient Neurologic Symptoms in a Woman With Migraine. <i>Headache</i> , 2015 , 55, 1274-82	4.2	0
41	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , 2013 , 16, 231-50	3.3	1264
40	The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. <i>Headache</i> , 2013 , 53, 427-36	4.2	256
39	Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. <i>Headache</i> , 2013 , 53, 1651-9	4.2	111
38	Evaluation for secondary causes of headache: the role of blood and urine testing. <i>Headache</i> , 2011 , 51, 338-45	4.2	13
37	The approach to the difficult patient. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2010 , 97, 233-8	3	2
36	Triptan therapy in migraine. <i>New England Journal of Medicine</i> , 2010 , 363, 63-70	59.2	141
35	Prophylaxis: headaches that never happen. <i>Headache</i> , 2008 , 48, 694-6	4.2	6

34	Tension-type headache. <i>BMJ, The</i> , 2008 , 336, 88-92	5.9	36
33	Hormonal management of migraine associated with menses and the menopause: a clinical review. <i>Headache</i> , 2007 , 47, 329-40	4.2	33
32	Menstrual migraine: pathophysiology, diagnosis, and impact. <i>Headache</i> , 2006 , 46 Suppl 2, S55-60	4.2	15
31	Headache attributed to psychiatric disorder: a case series. <i>Psychosomatics</i> , 2005 , 46, 326-33	2.6	8
30	Part II: clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. <i>Current Medical Research and Opinion</i> , 2005 , 21 Suppl 3, S8-12	2.5	5
29	Fixed drug combinations for the acute treatment of migraine : place in therapy. <i>CNS Drugs</i> , 2005 , 19, 769-84	6.7	21
28	Conclusion: how primary care physicians can help their patients with migraine. <i>The American Journal of Medicine: Supplement</i> , 2005 , 118 Suppl 1, 45S-46S		
27	Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2005 , 193, 636-49	6.4	69
26	General principles of migraine management: the changing role of prevention. <i>Headache</i> , 2005 , 45 Suppl 1, S33-47	4.2	57
25	Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. <i>Current Medical Research and Opinion</i> , 2005 , 21, 381-9	2.5	32
24	Off-label prescribing of drugs in specialty headache practice. <i>Headache</i> , 2004 , 44, 636-41	4.2	20
23	Migraine diagnosis and treatment. <i>Primary Care - Clinics in Office Practice</i> , 2004 , 31, 277-92, vi	2.2	1
22	Who will prescribe? A proposal for specialized opioid management clinics. <i>Pain Practice</i> , 2003 , 3, 218-21	3	
21	Safety of sumatriptan in pregnancy: a review of the data so far. <i>CNS Drugs</i> , 2003 , 17, 1-7	6.7	49
20	Naratriptan in the prophylaxis of cluster headache. <i>Headache</i> , 2002 , 42, 56-7	4.2	24
19	Volume and nature of telephone calls in a specialty headache practice. <i>Headache</i> , 2002 , 42, 883-7	4.2	12
18	A pilot study of pain and attitudes toward pain in a rehabilitation population. <i>Pain Medicine</i> , 2002 , 3, 333-8	2.8	3
17	Use of botulinum toxins for chronic headaches: a focused review. <i>Clinical Journal of Pain</i> , 2002 , 18, S169-76	3.6	38

- 16 Review: several drugs, especially triptans, are effective for pain relief in acute migraine. *ACP Journal Club*, **2002**, 137, 103
- 15 Review: Several drugs, especially triptans, are effective for pain relief in acute migraine. *ACP Journal Club*, **2002**, 137, 103
- 14 Missing dangerous causes of headache 38-53
- 13 Pitfalls in diagnostic testing: imaging and lumbar puncture 54-72
- 12 Errors in management of acute headache 100-118
- 11 Pitfalls in diagnostic testing: blood, urine, and other tests 73-83
- 10 Pitfalls in drug therapy to prevent headaches 119-144
- 9 Pitfalls in nonpharmacologic treatment of headache 145-161
- 8 Challenges and special situations in headache management 162-174
- 7 Confusing one benign headache with another 1-19
- 6 Mistaking primary headache for another condition 20-37
- 5 When historical or examination findings are missed or misinterpreted 84-99
- 4 Medicolegal pitfalls in headache management 175-185
- 3 STROBE-MR: Guidelines for strengthening the reporting of Mendelian randomization studies 9
- 2 Management of Headache in Women 257-268
- 1 Establishing a Coherent Reporting Guidelines Policy in Health Journals 308-317 1